How are focused therapeutic funds becoming increasingly important at pre-seed, seed and series A stages?
Prior to joining Nextech Invest as Partner in 2017, Jakob Loven, PhD, was a senior associate and strategic adviser at Third Rock Ventures in Cambridge, USA, a venture capital firm specialized in early stage healthcare investments. Dr Loven is an accomplished oncology-focused entrepreneur and life sciences venture capitalist. He co-founded in 2016 Relay Therapeutics in Cambridge, USA, and is also one of the scientific founders of Syros Pharmaceuticals, a biotechnology company launched in 2013 in Cambridge, USA. Dr Loven has completed his postdoctoral training at the Whitehead Institute for Biomedical Research in Cambridge, USA, where his work provided the foundational intellectual property of Syros Pharmaceuticals. He holds a PhD in Medical Sciences from the Karolinska Institutet in Stockholm, Sweden, and a BSc in in Natural Sciences from the University of Cambridge, England.